Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 15/20 | 0.57 |
| ▸ | SLC2A3 | P11169 | 14/20 | 0.53 |
| ▸ | SLC2A4 | P14672 | 14/20 | 0.53 |
| ▸ | SLC2A2 | P11168 | 6/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18485530 | 0.94 | SLC2A1 (0.61) | SLC2A1SLC2A3SLC2A4SLC2A2PTGER4 | |
| SCHEMBL16833375 | 0.90 | SLC2A1 (0.55) | SLC2A1SLC2A3SLC2A4SLC2A2PTGER4 | |
| SCHEMBL16832385 | 0.89 | SLC2A1 (0.70) | SLC2A1SLC2A3SLC2A4SLC2A2PTGER4 | |
| SCHEMBL16833024 | 0.87 | SLC2A1 (0.58) | SLC2A1SLC2A3SLC2A4SLC2A2PTGER4 | |
| SCHEMBL16855553 | 0.85 | SLC2A1 (0.75) | SLC2A1SLC2A3SLC2A4SLC2A2TP53 | |
| SCHEMBL18483262 | 0.84 | SLC2A1 (0.59) | SLC2A1SLC2A3SLC2A4SLC2A2PTGER4 | |
| SCHEMBL16833143 | 0.83 | SLC2A1 (0.60) | SLC2A1SLC2A3SLC2A4SLC2A2PTGER4 | |
| SCHEMBL16855671 | 0.83 | SLC2A1 (0.75) | SLC2A1SLC2A3SLC2A4SLC2A2PTGER4 | |
| SCHEMBL16832462 | 0.82 | SLC2A1 (0.73) | SLC2A1SLC2A3SLC2A4SLC2A2PTGER4 | |
| SCHEMBL18483840 | 0.81 | SLC2A1 (0.63) | SLC2A1SLC2A3SLC2A4SLC2A2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | claimed |
| EP-3083598-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-26 | — | — | EP | claimed |
| WO-2015091428-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | SLC2A1 1/4885SLC2A3 4/4885SLC2A4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.